DEA, SAMHSA Extend COVID-19 Telemedicine Flexibilities for Prescribing Controlled Medications through November 11, 2023. For more information, please see THIS ARITLE released by the US Drug Enforcement Administration.
Taking effect on May 11, 2023, the temporary rule extends the full set of telemedicine flexibilities adopted during the COVID-19 PHE for six months—through November 11, 2023. For any practitioner-patient telemedicine relationships that have been or will be established up to November 11, 2023, the full set of telemedicine flexibilities regarding prescription of controlled medications established during the COVID-19 PHE will be extended for one-year—through November 11, 2024.
Email to a Friend